A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher Parker, MD
The Royal Marsden Hospital, UK
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
134 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Liverpool, New South Wales, Australia
- Facility name not stated
Randwick, New South Wales, Australia
- Facility name not stated
St Leonards, New South Wales, Australia
- Facility name not stated
Sydney, New South Wales, Australia
- Facility name not stated
Wahroonga, New South Wales, Australia
- Facility name not stated
Wollongong, New South Wales, Australia
- Facility name not stated
Herston, Queensland, Australia
- Facility name not stated
Toowoomba, Queensland, Australia
- Facility name not stated
Adelaide, South Australia, Australia
- Facility name not stated
Woodville South, South Australia, Australia
- Facility name not stated
Hobart, Tasmania, Australia
- Facility name not stated
Fitzroy, Victoria, Australia
- Facility name not stated
Nedlands, Western Australia, Australia
- Facility name not stated
Kortrijk, Belgium
- Facility name not stated
Ottignies, Belgium
- Facility name not stated
Salvador, Estado de Bahia, Brazil
- Facility name not stated
Belo Horizonte, Minas Gerais, Brazil
- Facility name not stated
Porto Alegre, Rio Grande do Sul, Brazil
- Facility name not stated
Rio de Janeiro, Rio de Janeiro, Brazil
- Facility name not stated
Barretos, São Paulo, Brazil
- Facility name not stated
Piracicaba, São Paulo, Brazil
- Facility name not stated
São Paulo, São Paulo, Brazil
- Facility name not stated
Belo Horizonte, Brazil
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
London, Ontario, Canada
- Facility name not stated
Ottawa, Ontario, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Brno, Czechia
- Facility name not stated
Chomutov, Czechia
- Facility name not stated
Olomouc, Czechia
- Facility name not stated
Ostrava, Czechia
- Facility name not stated
Plzen - Bory, Czechia
- Facility name not stated
Prague, Czechia
- Facility name not stated
Usti n/Labem, Czechia
- Facility name not stated
La Roche-sur-Yon, France
- Facility name not stated
Montbéliard, France
- Facility name not stated
Saint-Cloud, France
- Facility name not stated
Ulm, Baden-Wurttemberg, Germany
- Facility name not stated
Hamburg, Free and Hanseatic City of Hamburg, Germany
- Facility name not stated
Frankfurt am Main, Hesse, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Jun 2008
- Primary completion
- 15 Jul 2011
- Completion
- 13 Feb 2014
- Last update posted
- 23 Feb 2026
- Registered enrollment
- 921
- Registry id
- NCT00699751
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.